This clinical trial is focused on studying the effects of a medication called Dupilumab on patients with uncontrolled moderate to severe Asthma. Asthma is a condition that affects the airways in the lungs, making it difficult to breathe. The study aims to see if Dupilumab can help prevent or slow down the decline in lung function over time. Dupilumab is given as a solution for injection using a pre-filled syringe. Some participants in the study will receive a placebo, which looks like the medication but does not contain the active ingredient.

The purpose of the study is to assess the long-term effects of Dupilumab on lung function in adults with moderate to severe asthma. Participants will be randomly assigned to receive either Dupilumab or a placebo. The study will last for a period of up to three years, during which participants will receive regular injections and attend scheduled visits to monitor their lung function and overall health. The study will help determine if Dupilumab can effectively prevent or reduce the rate of lung function decline in people with asthma.

Throughout the study, participants will undergo various assessments to track changes in their lung function and asthma symptoms. These assessments will include measuring the amount of air they can exhale forcefully, known as Forced Expiratory Volume (FEV1), and monitoring levels of a marker called FeNO, which indicates inflammation in the airways. The study will also evaluate the frequency of severe asthma attacks and any changes in asthma control and quality of life. The results will provide valuable information on the potential benefits of Dupilumab for individuals with moderate to severe asthma.